What is Beta Thalassemia Testing Market?
Beta thalassemia is a blood disorder in which the production of hemoglobin is reduced. Hemoglobin is the iron-containing protein in the red blood cells (RBCs) that carries oxygen to cells throughout the body. Thus people with beta thalassemia have low levels of hemoglobin which leads to a shortage of oxygen in many parts of the body. Pale skin, weakness, fatigue are the complications occur due to beta thalassemia. The people affecting with beta-thalassemia also have a risk of developing blood clots. Beta thalassemia testing includes Complete Blood Count (CBC), DNA testing, parental genetic testing, Chorionic Villus Sampling (CVS) and Preimplantation Genetic Diagnosis (PGD).
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Unit | Value (USD Million) |
Key Companies Profiled | Genorama Ltd. (Estonia), HiMedia Laboratories (India), DiagCor Bioscience Inc Ltd (China), Tosoh Bioscience, Inc. (United States), Goffin Molecular Technologies B.V. (Netherlands), Devyser (Sweden), Hybribio (China), Bio-Active Co., Ltd. (Thailand), Bio-Rad Laboratories (United States) and Genomed Biotech (United Kingdom) |
The market study is being classified, by Application (Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes and Pharmaceutical Industries) and major geographies with country level break-up. According to AMA, the Global Beta Thalassemia Testing market is expected to see steady growth rate.
Genorama Ltd. (Estonia), HiMedia Laboratories (India), DiagCor Bioscience Inc Ltd (China), Tosoh Bioscience, Inc. (United States), Goffin Molecular Technologies B.V. (Netherlands), Devyser (Sweden), Hybribio (China), Bio-Active Co., Ltd. (Thailand), Bio-Rad Laboratories (United States) and Genomed Biotech (United Kingdom) are some of the key players profiled in the study.
Global Beta Thalassemia Testing is a fragmented market due to the presence of various players. The companies are planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA predicts that United States and Chinese Players will contribute to the maximum growth of Global Beta Thalassemia Testing market throughout the forecasted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Beta Thalassemia Testing market by Type, Application and Region.
On the basis of geography, the market of Beta Thalassemia Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Growing Number of Patients Suffering From Beta Thalassemia
- Development of Various Rapid Diagnostic Methods
Market Trend
- Use of Preimplantation Genetic Diagnosis (PGD)
Restraints
- High Implementation Cost of Sophisticated Clinical and Preclinical Imaging Systems
Opportunities
- Increasing Prevalence of Thalassemia
Challenges
- Lack of Awareness about the Disorder
Market Leaders and some development strategies
On 14th October 2021, Tosoh Bioscience, Inc. acquired Semba Biosciences. With this acquisition, Tosoh will able to offer unparalleled efficiency and productivity in downstream processes and significantly decrease the cost of manufacturing.
In 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. The transaction includes further progress relating to the patent estate for REVLIMID, the U.S. Food and Drug Administration (FDA) approval of INREBIC (fedratinib) for the treatment of certain forms of myelofibrosis, the U.S. FDA approval of REBLOZYL (luspatercept-aamt) for the treatment of anemia in certain adult patients with beta thalassemia, and regulatory filings of luspatercept and ozanimod in the U.S. and Europe.
As per the Standards of Care Guideline, All patients should undergo at least an annual comprehensive assessment at a thalassemia center. During such an assessment, recommendations are summarized after consultation with multiple specialists and communicated directly to the primary provider and family.
Key Target Audience
Technology Investors, Research Professionals, Research Institutes, Government Body & Associations and End-user